Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma

Histopathology

Volumn 66, Issue 2, 2015, Pages 234-243

  Kaira, Kyoichi ^a   Sunose, Yutaka ^a   Arakawa, Kazuhisa ^b   Sunaga, Noriaki ^a   Shimizu, Kimihiro ^a   Tominaga, Hideyuki ^a   Oriuchi, Noboru ^a   Nagamori, Shushi ^c   Kanai, Yoshikatsu ^c   Oyama, Tetsunari ^a   Takeyoshi, Izumi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MAEBASHI RED CROSS HOSPITAL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Amino acid transporter; ASCT2; Pancreatic cancer; Prognostic factor

Indexed keywords

AMINO ACID TRANSPORTER; ASC AMINO ACID TRANSPORTER 2; CD34 ANTIGEN; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; LAT1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; SLC1A5 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION; BIOSYNTHESIS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

MAMMALIA;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID TRANSPORT SYSTEM ASC; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925332053     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12464     Document Type: Article

References (38)

1. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol. Rev. 1990; 70; 43-77.
2. Kekuda R, Prasad PD, Fei YJ et al. Cloning of the sodiumdependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line. J. Biol. Chem. 1996; 271; 18657-18661.
3. Fuch BC, Finger RE, Onan MC et al. ASCT2 silencing regulates mammalian target of rapamycin growth and survival signaling in human hepatoma cells. Am. J. Physiol. Cell Physiol. 2007; 293; C55-C63.
4. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin. Cancer Biol. 2006; 15; 254-266.
5. Okudaira H, Hirano N, Nishii R et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J. Nucl. Med. 2011; 52; 822-829.
6. Nakanishi T, Tamai I. Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J. Pharm. Sci. 2011; 100; 3731-3750.
7. Li R, Younes M, Frolov A et al. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 2003; 23; 3413-3418.
8. Whitte D, Ali N, Carlson N et al. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res. 2002; 22; 2555-2557.
9. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009; 121; 29-40.
10. Baek S, Choi CM, Ahn SH et al. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC-transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin. Cancer Res. 2012; 18; 5427-5437.
11. Kanai Y, Segawa H, Miyamoto K et al. Expression, cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 1998; 273; 23629-23632.
12. Yanagida O, Kanai Y, Chairoungdua A et al. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta 2001; 1514; 291-302.
13. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J. Surg. Oncol. 2005; 90; 233-238.
14. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br. J. Cancer 2008; 98; 742-748.
15. Nakanishi K, Ogata S, Matsuo H et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2007; 451; 681-690.
16. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int. J. Cancer 2006; 119; 484-492.
17. Sakata T, Ferdous G, Tsuruta T et al. L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol. Int. 2009; 59; 7-18.
18. Ichinoe M, Mikami T, Yoshida T et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol. Int. 2011; 61; 281-289.
19. Furuya M, Horiguchi J, Nakajima H et al. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012; 103; 382- 389.
20. Kaira K, Oriuchi N, Takahashi T et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am. J. Transl. Res. 2011; 3; 468- 478.
21. Kaira K, Sunose Y, Arakawa K et al. Prognostic significance of L-type amino acid transporter 1 expression in surgically resected pancreatic cancer. Br. J. Cancer 2012; 107; 632-638.
22. Sobin LH, Gospodarowicz MK, Wittekind Ch eds. International Union Against Cancer (UICC) TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell, 2009.
23. Altman A, Cardenas JM, Houghten RA et al. Antibodies of predetermined specificity against chemically synthesized peptides of human interleukin 2. Proc. Natl Acad. Sci. USA 1984; 81; 2176-2180.
24. Chairoungdua A, Kanai Y, Matsuo H et al. Identification and characterization of a novel member of the heterodimeric amino acid transporter family presumed to be associated with an unknown heavy chain. J. Biol. Chem. 2001; 276; 49390- 49399.
25. Khunweeraphong N, Nagamori S, Wiriyasermkul P et al. Lglutamate enhances methylmercury toxicity by synergistically increasing oxidative stress. J. Pharmacol. Sci. 2012; 119; 368- 380.
26. Shimizu K, Kaira K, Tomizawa Y et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br. J. Cancer 2014; 110; 2030-2039.
27. Oppedisano F, Catto M, Koutentis PA et al. Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol. Appl. Pharmacol. 2012; 93; 93-102.
28. Kim CS, Moon IS, Park JH et al. Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells. Biol. Pharm. Bull. 2010; 33; 1117-1121.
29. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010; 35; 427- 433.
30. Son J, Lyssiotis CA, Ying H et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496; 101-105.
31. Hassanein M, Hoeksema MD, Shiota M et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin. Cancer Res. 2013; 19; 560-570.
32. Wang Q, Beaumont KA, Otte NJ et al. Targeting glutamine transport to suppress melanoma cell growth. Int. J. Cancer 2014; Sep 1; 135(5); 1060-71.
33. Willems L, Jacque N, Jacquel A et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013; 122; 3521-3532.
34. Mullen AR, Wheaton WW, Jin ES et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481; 385-388.
35. Fendt SM, Bell EL, Keibler MA et al. Reductive glutamine metabolism is a function of the a-ketoglutarate to citrate ratio in cells. Nat. Commun. 2013; 4; 2236.
36. Albers T, Marsiglia W, Thomas T et al. Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) ligands with novel serine analogs. Mol. Pharmacol. 2012; 81; 356-365.
37. Fan X, Ross DD, Arakawa H et al. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with proliferative aminopeptidase inhibitors. Biochem. Pharmacol. 2010; 80; 811-818.
38. Imai H, Kaira K, Oriuchi N et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res. 2010; 30; 4819-4828.